Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Catalent

Revenues up 23% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent
1Q Revenues: $543.9 million (+23%)
1Q Earnings: $3.8 million (-17%)
Comments: Softgel Technologies revenue was $219.7 million in the quarter, up 18%. Growth was primarily attributable to the February 2017 Accucaps acquisition, which contributed 14 percentage points. Drug Delivery Solutions revenue was $225.8 million, up 18% primarily driven by favorable demand for certain higher margin offerings, primarily U.S. operations for oral delivery platform, and increased volume from biologics offerings, partially offset by a decrease in product participation revenue. Revenue from the Clinical Supply Services segment was $109.7 million, up 46%, due to higher volume related to storage, distribution, manufacturing, and packaging services; as well as increased lower-margin comparator sourcing activities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters